Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02273726 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
A Phase 3 study, sponsored by Kyntra Bio.
- Completed
- Registry status
- Phase 3
- Development phase
- 741
- Enrollment target
NCT02273726 is a Phase 3 study that has completed, run by Kyntra Bio. The registered enrollment target is 741 participants.
The verdict
NCT02273726, a Phase 3 study, has completed, sponsored by Kyntra Bio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 741 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy and safety of roxadustat compared with active control (epoetin alfa) for the maintenance treatment of anemia in participants with ESRD on dialysis.
Interventions
- DRUG Epoetin Alfa
- DRUG Roxadustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 741 participants |
| Start Date | 2015-01-15 |
| Est. Completion | 2018-09-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02273726
The ClinicalTrials.gov registry entry for NCT02273726 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 741 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Epoetin Alfa is the first listed.
NCT02273726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02273726 about?
NCT02273726 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis". The primary objective of this study is to evaluate the efficacy and safety of roxadustat compared with active control (epoetin alfa) for the maintenance treatment of anemia in participants with ESRD on dialysis.
What is the current status of trial NCT02273726?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 741 participants. The study started on 2015-01-15. Estimated completion is 2018-09-19.
What interventions are being tested in trial NCT02273726?
The interventions under investigation include: Epoetin Alfa (DRUG), Roxadustat (DRUG).
Who is sponsoring clinical trial NCT02273726?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.